Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Social Anxiety Disorder
NCT05571592Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jan 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Social Anxiety Disorder (SAD) (3 arms), sponsored by NYU Langone Health. Primary endpoints: Visual Analogue Mood Scale at Week 2, Amygdala Beta-Weights in Activation in Response to Intensely Fearful Faces versus Neutral Faces as Measured by fMRI at Week 3 and 1 more. Started Jan 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT05571592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571592.